keyword
https://read.qxmd.com/read/38529379/case-report-immunotherapy-in-rare-high-tmb-pancreatic-acinar-carcinoma
#41
Guifu Wu, Yuting Fang, Deying Bi, Wenwei Yang, Yongkun Sun
This case report details a patient with Pancreatic Acinar Cell Carcinoma (PACC), a rare malignancy with distinctive biological and imaging features. In the absence of standardized treatment protocols for PACC, we embarked on a diagnostic journey that led to the adoption of an innovative therapeutic regimen in our institution. A 45-year-old female patient presented with a pancreatic mass, which was histologically confirmed as PACC following a biopsy. Subsequent genomic profiling revealed a high tumor mutational burden (21...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38526693/from-skin-to-solution-exploring-epicutaneous-immunotherapy-for-peanut-allergy-a-systematic-review-and-meta-analysis
#42
REVIEW
Umm E Salma Shabbar Banatwala, Muhammad Moiz Nasir, Reema Javed, Areeba Ahmed, Syed Ali Farhan, Ali Ajam
Peanut allergy is a leading cause of severe food reactions. This meta-analysis evaluates the efficacy and safety of epicutaneous immunotherapy (EPIT) compared to placebo for peanut-allergic individuals. After prospectively registering on PROSPERO, we searched three databases (PubMed, Google Scholar, and Cochrane CENTRAL) and 2 trial registries till September 2023. Analysis was conducted via RevMan where data was computed using risk ratios (RR). The Cochrane Risk of Bias tool and GRADE criteria were used to appraise and evaluate the evidence...
March 25, 2024: Clinical Reviews in Allergy & Immunology
https://read.qxmd.com/read/38522139/single-cell-transcriptome-profiling-of-infrapatellar-fat-pad-highlights-the-role-of-interstitial-inflammatory-fibroblasts-in-osteoarthritis
#43
JOURNAL ARTICLE
Hongxu Pu, Chenghao Gao, Yi Zou, Liming Zhao, Guanghao Li, Changyu Liu, Libo Zhao, Meng Zheng, Gaohong Sheng, Xuying Sun, Xingjie Hao, Chaolong Wang, Ximiao He, Jun Xiao
OBJECTIVES: Osteoarthritis (OA) is a whole-joint disease in which the role of the infrapatellar fat pad (IFP) in its pathogenesis is unclear. Our study explored the cellular heterogeneity of IFP to understand OA and identify therapeutic targets. METHODS: Single-cell and single-nuclei RNA sequencing were used to analyze 10 IFP samples, comprising 5 from OA patients and 5 from healthy controls. Analyses included differential gene expression, enrichment, pseudotime trajectory, and cellular communication, along with comparative studies with visceral and subcutaneous fats...
March 23, 2024: International Immunopharmacology
https://read.qxmd.com/read/38513730/impact-of-conjugation-to-different-lipids-on-the-lymphatic-uptake-and-biodistribution-of-brush-peg-polymers
#44
JOURNAL ARTICLE
Mohammad Abdallah, Lihuan Lin, Ian K Styles, Alexander Mörsdorf, James L Grace, Gracia Gracia, Cornelia B Landersdorfer, Cameron J Nowell, John F Quinn, Michael R Whittaker, Natalie L Trevaskis
Delivery to peripheral lymphatics can be achieved following interstitial administration of nano-sized delivery systems (nanoparticles, liposomes, dendrimers etc) or molecules that hitchhike on endogenous nano-sized carriers (such as albumin). The published work concerning the hitchhiking approach has mostly focussed on the lymphatic uptake of vaccines conjugated directly to albumin binding moieties (ABMs such as lipids, Evans blue dye derivatives or peptides) and their subsequent trafficking into draining lymph nodes...
March 19, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38511232/immune-checkpoint-inhibitor-monotherapy-is-sufficient-to-promote-microenvironmental-normalization-via-the-type-i%C3%A2-interferon-pathway-in-pd-l1-expressing-head-and-neck-cancer
#45
JOURNAL ARTICLE
Jeon Yeob Jang, Bok-Soon Lee, Mei Huang, Chorong Seo, Ji-Hye Choi, Yoo Seob Shin, Hyun Goo Woo, Chul-Ho Kim
Immune checkpoint blockers (ICBs) targeting programmed cell death protein 1 (PD-1) have been proven to be an effective first-line therapy against programmed cell death 1 ligand 1 (PD-L1; also known as CD274 molecule)-expressing head and neck squamous cell carcinoma (HNSCC) in recent KEYNOTE-048 trial. However, associated changes in the tumor microenvironment (TME) and underlying mechanisms remain elusive. Oral tumors in C57/BL6 mice were induced by administering 7,12-dimethylbenzanthracene into the buccal mucosa...
March 21, 2024: Molecular Oncology
https://read.qxmd.com/read/38511087/pharmacokinetics-safety-and-efficacy-of-20-subcutaneous-immunoglobulin-ig20gly-administered-weekly-or-every-2-weeks-in-japanese-patients-with-primary-immunodeficiency-diseases-a-phase-3-open-label-study
#46
JOURNAL ARTICLE
Hirokazu Kanegane, Akifumi Endo, Satoshi Okada, Hidenori Ohnishi, Masataka Ishimura, Ryuta Nishikomori, Kohsuke Imai, Shigeaki Nonoyama, Hideki Muramatsu, Taizo Wada, Atsushi Kuga, Ko Sakamoto, Sharon Russo-Schwarzbaum, Liang-Hui Chu, Barbara McCoy, Zhaoyang Li, Leman Yel
This phase 3, open-label, multidose study (NCT04346108) evaluated the pharmacokinetics, safety, tolerability, and efficacy of immunoglobulin subcutaneous (human) 20% solution (Ig20Gly) administered weekly and every 2 weeks in Japanese patients with primary immunodeficiency diseases (PIDs). The study was conducted at eight study sites in Japan and enrolled patients aged ≥2 years with PIDs treated using a stable intravenous immunoglobulin dose for ≥3 months prior to the study. Patients received intravenous immunoglobulin every 3 or 4 weeks at pre-study dose (200-600 mg/kg) for 13 weeks (Epoch 1), subcutaneous Ig20Gly (50-200 mg/kg) once weekly for 24 weeks (Epoch 2), and Ig20Gly (100-400 mg/kg) every 2 weeks for 12 weeks (Epoch 3)...
2024: Immunotherapy advances
https://read.qxmd.com/read/38509769/mait-cells-are-associated-with-responsiveness-to-neoadjuvant-immunotherapy-in-copd-associated-nsclc
#47
JOURNAL ARTICLE
Yanze Yin, Ao Zeng, Abudumijiti Abuduwayiti, Zhilong Xu, Keyi Chen, Chao Wang, Xinyun Fang, Jiarui Wang, Gening Jiang, Jie Dai
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) experience worse clinical outcomes but respond better to immunotherapy than patients with NSCLC without COPD. Mucosal-associated invariant T (MAIT) cells, a versatile population of innate immune T lymphocytes, have a crucial function in the response to infection and tumors. This study investigated the distribution of MAIT cells in COPD-associated NSCLC and their involvement in the immune response...
March 2024: Cancer Medicine
https://read.qxmd.com/read/38508096/kimura-s-disease-treated-with-dupilumab-a-case-report-and-literature-review
#48
JOURNAL ARTICLE
Si-Yu Luo, Kai-Yi Zhou, Qin-Xiao Wang, Li-Jia Deng, Sheng Fang
BACKGROUND: Kimura's disease (KD) is a rare chronic inflammatory disorder characterised by painless, deep subcutaneous nodules that most commonly affect the head and neck region of Asian men. Due to high relapse rates and side effects of current therapies, the treatment of KD is challenging. OBJECTIVES: To present a case of KD that was successfully treated with dupilumab and to review the literature with a focus on the evaluation of the efficacy and safety of dupilumab in KD...
March 19, 2024: International Immunopharmacology
https://read.qxmd.com/read/38506658/targeting-two-radiation-induced-immunosuppressive-pathways-to-improve-the-efficacy-of-normofractionated-radiation-therapy-in-a-preclinical-colorectal-cancer-model
#49
JOURNAL ARTICLE
Jihane Boustani, Benoit Lecoester, Jérémy Baude, Charlène Latour, Emeric Limagne, Riad Ladjohoulou, Véronique Morgand, Lisa Froidurot, François Ghiringhelli, Gilles Truc, Olivier Adotévi, Céline Mirjolet
PURPOSE: We have previously demonstrated in a murine colorectal cancer model that normofractionated RT (normoRT: 18 × 2 Gy) induced MDSC infiltration and PD-L1 expression, while hypofractionated RT (hypoRT: 3 × 8 Gy) induced Treg. Here, we wanted to assess whether the association of normoRT with treatments that target two radiation-induced immunosuppressive pathways (MDSC and PD-L1) could improve tumor control. MATERIALS AND METHODS: Subcutaneous tumors were induced using colon tumor cells (CT26) in immunocompetent mice (BALB/c) and were treated with RT alone (18 × 2 Gy or 3 × 8 Gy), or concomitantly with 5-Fluorouracil (5FU) (10 mg/kg) to deplete MDSC, and/or anti-PD-L1 (10 mg/kg)...
March 20, 2024: International Journal of Radiation Biology
https://read.qxmd.com/read/38505675/introduction-of-a-new-recombinant-vaccine-based-on-grp78-for-breast-cancer-immunotherapy-and-evaluation-in-a-mouse-model
#50
JOURNAL ARTICLE
Hamed Zare, Hamid Bakherad, Arman Nasr Esfahani, Mohamad Norouzi, Hossein Aghamollaei, Seyed Latif Mousavi Gargari, Fatemeh Mahmoodi, Mahdi Aliomrani, Walead Ebrahimizadeh
INTRODUCTION: Breast cancer is one of the most prevalent malignancies in women. Several treatment options are available today, including surgery, chemotherapy, and radiotherapy. Immunotherapy, as a highly specific therapy, involves adaptive immune responses and immunological memory. In our present research, we used the recombinant C-terminal domain of the GRP78 (glucose- regulated protein 78) protein to induce an immune response and investigate its therapeutic impact in the 4T1 breast cancer model...
2024: BioImpacts: BI
https://read.qxmd.com/read/38499351/subcutaneous-pythiosis-in-human-treated-successfully-with-antimicrobial-treatment-debridement-and-immunotherapy
#51
JOURNAL ARTICLE
Moni Roy, Joel Borden, Douglas J Kasper
Pythiosis is caused due to a filamentous eukaryotic micro-organism called Pythium insidiosum and the disease occurs commonly in horses and cattle. Subcutaneous pythiosis infection in humans is rare with no clear clinical guidelines for treatment. We present a case of a man in his 20s with non-resolving ulcers noted over lower extremity after exposure to swamp water draining animal remains. The patient received several courses of oral antibiotics with no improvement in symptoms before getting admitted to our institution...
March 18, 2024: BMJ Case Reports
https://read.qxmd.com/read/38490214/the-liver-as-a-cytokine-factory-working-on-mrna-blueprints-for-cancer-immunotherapy
#52
JOURNAL ARTICLE
Pedro Berraondo, Gabriel Gomis, Ignacio Melero
mRNA has the potential to encode both vaccines and immunomodulatory proteins for cancer immunotherapy. In this issue, Beck et al. report on lipopolyplexed mRNAs encoding albumin-stabilized interleukin-2 to transduce liver cells. These mRNAs attain antitumor efficacy on subcutaneous mouse tumors even if malignant cells lack major histocompatibility complex class I (MHC class I) expression.
April 8, 2024: Cancer Cell
https://read.qxmd.com/read/38487528/a-phase-i-trial-of-son-1010-a-tumor-targeted-interleukin-12-linked-albumin-binding-cytokine-shows-favorable-pharmacokinetics-pharmacodynamics-and-safety-in-healthy-volunteers
#53
JOURNAL ARTICLE
Richard T Kenney, John K Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Isabelle Kuan, Sant P Chawla, Thomas M Polasek, Jason Lickliter, Philip J Ryan
BACKGROUND: The benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 study required careful attention to revised dosing strategies. Despite some signs of efficacy since then, most rIL-12 clinical trials have encountered hurdles such as short terminal elimination half-life (T½ ), limited tumor microenvironment targeting, and substantial systemic toxicity...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38483174/nasal-allergen-neutralizing-antibodies-correlate-closely-with-tolerated-intranasal-allergen-challenge-dose-following-grass-pollen-subcutaneous-immunotherapy-in-patients-with-local-allergic-rhinitis
#54
JOURNAL ARTICLE
Ibon Eguiluz-Gracia, Rebecca V Parkin, Janice A Layhadi, Elizabeth Palmer, Xun Meng, Rongfei Zhu, Umit Sahiner, Stephen R Durham, Maria Jose Torres, Cristobalina Mayorga, Carmen Rondon, Mohamed H Shamji
BACKGROUND: Local allergic rhinitis (LAR) is defined by chronic nasal symptoms, absence of atopy, positive nasal allergen challenge (NAC) and a good response to subcutaneous allergen immunotherapy (SCIT). We sought to investigate SCIT capacity to induce local and systemic blocking antibodies in LAR patients. METHODS: A RDBPC study of grass SCIT was performed, with participants receiving either SCIT (Group A; n = 10) or placebo (Group B; n = 14) in the first 6 months...
March 14, 2024: Allergy
https://read.qxmd.com/read/38482006/comparison-of-the-therapeutic-effects-of-medication-therapy-specific-immunotherapy-and-anti-ige-omalizumab-in-patients-with-hay-fever
#55
JOURNAL ARTICLE
Rui Tang, Xiaohong Lyu, Yibo Hou, Yongshi Yang, Guodong Fu, Liping Zhu, Lu Xue, Hong Li, Ruiqi Wang
BACKGROUND: Hay fever, characterized by seasonal allergic reactions, poses a significant health challenge. Existing therapies encompass standard drug regimens, biological agents, and specific immunotherapy. This study aims to assess and compare the effectiveness of anti-IgE (omalizumab), medication therapy, and subcutaneous immunotherapy (SCIT) for hay fever. METHODS: Conducted as a retrospective cohort study, this research involved 98 outpatient hay fever patients who underwent routine medication, omalizumab treatment, or SCIT before the onset of the spring pollen season...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38481806/nk-92mi-cells-engineered-with-anti-claudin-6-chimeric-antigen-receptors-in-immunotherapy-for-ovarian-cancer
#56
JOURNAL ARTICLE
Junping Li, Hong Hu, Hui Lian, Shuo Yang, Manting Liu, Jinping He, Bihui Cao, Dongni Chen, Yuling Hu, Chen Zhi, Yan Shen, Xiaodie Ye, Bingjia He, Ming Zhao, Weijun Fan, Linfeng Xu, Rom Leidner, Qingde Wu, Lili Yang, Zhenfeng Zhang
Background : The application of chimeric antigen receptor (CAR) NK cells in solid tumors is hindered by lack of tumor-specific targets and inefficient CAR-NK cell efficacy. Claudin-6 (CLDN6) has been reported to be overexpressed in ovarian cancer and may be an attractive target for CAR-NK cells immunotherapy. However, the feasibility of using anti-CLDN6 CAR-NK cells to treat ovarian cancer remains to be explored. Methods : CLDN6 expression in primary human ovarian cancer, normal tissues and cell lines were detected by immunohistochemistry and western blot...
2024: International Journal of Biological Sciences
https://read.qxmd.com/read/38480774/interferon-%C3%AE-in-the-tumor-microenvironment-promotes-the-expression-of-b7h4-in-colorectal-cancer-cells-thereby-inhibiting-cytotoxic-t-cells
#57
JOURNAL ARTICLE
Zhi-Liang Jing, Guang-Long Liu, Na Zhou, Dong-Yan Xu, Na Feng, Yan Lei, Li-Li Ma, Min-Shan Tang, Gui-Hui Tong, Na Tang, Yong-Jian Deng
The bioactivity of interferon-γ (IFN-γ) in cancer cells in the tumor microenvironment (TME) is not well understood in the current immunotherapy era. We found that IFN-γ has an immunosuppressive effect on colorectal cancer (CRC) cells. The tumor volume in immunocompetent mice was significantly increased after subcutaneous implantation of murine CRC cells followed by IFN-γ stimulation, and RNA sequencing showed high expression of B7 homologous protein 4 (B7H4) in these tumors. B7H4 promotes CRC cell growth by inhibiting the release of granzyme B (GzmB) from CD8+ T cells and accelerating apoptosis in CD8+ T cells...
March 13, 2024: Scientific Reports
https://read.qxmd.com/read/38473271/tumoral-c2-regulates-the-tumor-microenvironment-by-increasing-the-ratio-of-m1-m2-macrophages-and-tertiary-lymphoid-structures-to-improve-prognosis-in-melanoma
#58
JOURNAL ARTICLE
Gengpu Zhang, Shengnan Li, Wanyi Xiao, Chao Zhang, Ting Li, Zhichao Liao, Haotian Liu, Ruwei Xing, Wei Yao, Jilong Yang
Immunotherapy is an essential therapy for individuals with advanced melanoma. However, not all patients respond to such treatment due to individual differences. We conducted a multidimensional analysis using transcriptome data from our center, as well as publicly available databases. We found that effective nivolumab treatment led to an upregulation of C2 levels, and higher levels following treatment are indicative of a good outcome. Through bioinformatics analyses and immunofluorescence, we identified a correlation between C2 and M1 macrophages...
February 23, 2024: Cancers
https://read.qxmd.com/read/38466366/multiple-immunomodulatory-strategies-based-on-targeted-regulation-of-proprotein-convertase-subtilisin-kexin-type-9-and-immune-homeostasis-against-hepatocellular-carcinoma
#59
JOURNAL ARTICLE
Shiji Fang, Liyun Zheng, Gao-Feng Shu, Chen Xiaoxiao, Xiaoju Guo, Yiming Ding, Wenjing Yang, Jiale Chen, Zhongwei Zhao, Jianfei Tu, Minjiang Chen, Jian-Song Ji
Immunotherapy is the most promising systemic therapy for hepatocellular carcinoma. However, the outcome remains poor. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a role in altering cell-surface protein levels, potentially undermining the efficacy of immunotherapy against tumors. This highlights its potential as a target for antitumor therapy. Herein, CaCO3 -based nanoparticles coencapsulated with DOX, an immunogenic cell death (ICD) inducer, and evolocumab was developed to enhanced the efficacy of immunotherapy...
March 11, 2024: ACS Nano
https://read.qxmd.com/read/38465206/drug-loaded-tumor-derived-microparticles-elicit-cd8-t-cell-mediated-anti-tumor-response-in-hepatocellular-carcinoma
#60
JOURNAL ARTICLE
Yulin Chen, Yi Zhang, Jianjun Wang, Xiong Cai, Junzhang Chen, Xiaobo Min, Yunjie Xu, Qi Qin, Chidan Wan
BACKGROUND: Hepatocellular Carcinoma (HCC) poses significant challenges due to limited effective treatments and high recurrence rates. Immunotherapy, a promising approach, faces obstacles in HCC patients due to T-cell exhaustion and immunosuppression within the tumor microenvironment. METHODS: Using doxorubicin-loaded tumor-derived microparticles (Dox-TMPs), the mice with H22 ascites model and subcutaneous tumors model were treated. Following the treatment, mice were re-challenged with H22 cells to compare the therapeutic effects and recurrence among different groups of mice, alongside examining the changes in the proportions of immune cells within the tumor microenvironment...
2024: International Journal of Nanomedicine
keyword
keyword
54124
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.